Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) EPS (Weighted Average and Diluted) (2020 - 2025)

Oncology Institute's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.05 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 66.67% year-over-year to -$0.05; the TTM value through Dec 2025 reached -$0.55, up 23.61%, while the annual FY2025 figure was -$0.54, 23.94% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.05 in Q4 2025 per TOI's latest filing, up from -$0.14 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.21 in Q1 2022 to a low of -$0.33 in Q1 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.13, with a median of -$0.16 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 221691361.25% in 2021, then skyrocketed 1150.0% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.15 in 2021, then decreased by 20.0% to -$0.18 in 2022, then dropped by 16.67% to -$0.21 in 2023, then increased by 28.57% to -$0.15 in 2024, then skyrocketed by 66.67% to -$0.05 in 2025.
  • Per Business Quant, the three most recent readings for TOI's EPS (Weighted Average and Diluted) are -$0.05 (Q4 2025), -$0.14 (Q3 2025), and -$0.15 (Q2 2025).